Last $28.60 USD
Change Today +0.30 / 1.06%
Volume 30.8M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 8:04 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by PFIZER INC (PFE) in the last 6 months

Announced 07/30/14
635.00M for Baxter International Inc., Two Commercially Marketed Vaccines and Related Production Facilities
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire two commercially marketed vaccines and related production facilities from Baxter International Inc. (NYSE:BAX) for approximately $640 million on July 30, 2014. The consideration is subject to certain adjustments. The transaction is subject to regulatory approvals, including some countries in the European Union, and other customary closing conditions. The transaction has been approved by Czech antitrust ...
Read More


PFE's price was unchanged after the transaction was announced on 07/30/14.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
Baxter International Inc.
 
Announced 07/16/14
360.00M for InnoPharma, LLC
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) entered into an agreement to acquire InnoPharma, Inc. from Thomas, McNerney & Partners, NXT Capital Venture Finance and others for approximately $400 million on July 16, 2014. Pfizer will make an upfront cash payment of $225 million and up to $135 million of contingent milestone payments. The transaction is subject to U.S. regulatory approval and is expected to close during the third quarter of 2014. Lowell Dashefsky, Aaron Gardner, Viktoriya Karshenboyem, ...
Read More


PFE's price was unchanged after the transaction was announced on 07/16/14.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
Comerica Bank
NXT Capital Venture Finance
Thomas, McNerney & Partners
Financial Advisor
JPMorgan Chase & Co.
Legal Advisor
Morgan, Lewis & Bockius LLP
 
Announced 07/8/14
55.00M for Pfizer Inc., 87 and 200 Cambridge Park Drive
Merger/Acquisition

King Street Properties LLC acquired 87 and 200 Cambridge Park Drive from Pfizer Inc. (NYSE:PFE) for $54.5 million in May 2014. King Street secured financing of $89 million from Cornerstone Real Estate Advisers for acquisition and repositioning of the vacant office/lab facilities. $22 million loan is secured for 87 Cambridge Park Drive and $67 million for 200 Cambridge Park Drive. Greg LaBine of HFF acted on behalf of King Street Properties.


PFE's price was unchanged after the transaction was announced on 07/8/14.
Investor / Buyer
King Street Properties LLC
Creditor / Lender
Pfizer Inc.
 
Announced 04/28/14
75.55B for AstraZeneca PLC
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) made a possible offer to acquire AstraZeneca PLC (LSE:AZN) from BlackRock, Inc. (NYSE:BLK) and others for £62.7 billion on April 26, 2014. Pfizer is considering a possible transaction, to be paid in a combination of cash and shares in the combined entity. Pfizer Inc. will pay £15.9 per share as cash and 1.845 stocks per share of AstraZeneca PLC. The transaction, if consummated, is expected to result in the combination of the two companies under ...
Read More


PFE's price was unchanged after the transaction was announced on 04/28/14.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
BlackRock, Inc.
Investor AB
Financial Advisor
Centerview Partners LLC
Evercore Partners International LLP
Goldman Sachs International
Morgan Stanley & Co. International plc
Robey Warshaw LLP
Legal Advisor
Davis Polk & Wardwell LLP
Freshfields Bruckhaus Deringer LLP
 
Announced 04/28/14
64.17B for AstraZeneca PLC
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) made a preliminary and conditional proposal to acquire AstraZeneca PLC (LSE:AZN) for £58 billion in cash and stock on January 5, 2014. Under the terms, Pfizer would pay £13.98 in cash and issue 1.758 Pfizer shares for each share of AstraZeneca. The combined company will be listed and headquartered in United States. Fares Noujaim, Adrian Mee, Michael Findlay and Geoff Iles of Merrill Lynch, Pierce, Fenner & Smith Inc and Merrill Lynch International ...
Read More


PFE's price was unchanged after the transaction was announced on 04/28/14.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
Investor AB
Financial Advisor
Evercore Partners International LLP
Goldman Sachs International
Morgan Stanley & Co. International plc
Robey Warshaw LLP
Legal Advisor
Davis Polk & Wardwell LLP
Freshfields Bruckhaus Deringer LLP
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $28.60 USD +0.30

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €106.50 EUR -0.16
Gilead Sciences Inc $107.18 USD +1.09
Merck & Co Inc $56.63 USD +1.12
Novartis AG SFr.85.60 CHF +0.20
Procter & Gamble Co/The $83.23 USD -1.00
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 17.8x
Price/Sales 3.6x
Price/Book 2.3x
Price/Cash Flow 12.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.